These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24411134)

  • 1. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease.
    Rafii MS; Baumann TL; Bakay RA; Ostrove JM; Siffert J; Fleisher AS; Herzog CD; Barba D; Pay M; Salmon DP; Chu Y; Kordower JH; Bishop K; Keator D; Potkin S; Bartus RT
    Alzheimers Dement; 2014 Sep; 10(5):571-81. PubMed ID: 24411134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial.
    Rafii MS; Tuszynski MH; Thomas RG; Barba D; Brewer JB; Rissman RA; Siffert J; Aisen PS;
    JAMA Neurol; 2018 Jul; 75(7):834-841. PubMed ID: 29582053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmortem Analysis in a Clinical Trial of AAV2-NGF Gene Therapy for Alzheimer's Disease Identifies a Need for Improved Vector Delivery.
    Castle MJ; Baltanás FC; Kovacs I; Nagahara AH; Barba D; Tuszynski MH
    Hum Gene Ther; 2020 Apr; 31(7-8):415-422. PubMed ID: 32126838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease.
    Mandel RJ
    Curr Opin Mol Ther; 2010 Apr; 12(2):240-7. PubMed ID: 20373268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons.
    Bishop KM; Hofer EK; Mehta A; Ramirez A; Sun L; Tuszynski M; Bartus RT
    Exp Neurol; 2008 Jun; 211(2):574-84. PubMed ID: 18439998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases.
    Herzog CD; Bishop KM; Brown L; Wilson A; Kordower JH; Bartus RT
    Drug Deliv Transl Res; 2011 Oct; 1(5):361-82. PubMed ID: 25788422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene and cell therapy for the nucleus basalis of Meynert with NGF in Alzheimer's disease.
    Eriksdotter M; Mitra S
    Handb Clin Neurol; 2021; 179():219-229. PubMed ID: 34225964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery.
    Wahlberg LU; Lind G; Almqvist PM; Kusk P; Tornøe J; Juliusson B; Söderman M; Selldén E; Seiger Å; Eriksdotter-Jönhagen M; Linderoth B
    J Neurosurg; 2012 Aug; 117(2):340-7. PubMed ID: 22655593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease.
    Eriksdotter-Jönhagen M; Linderoth B; Lind G; Aladellie L; Almkvist O; Andreasen N; Blennow K; Bogdanovic N; Jelic V; Kadir A; Nordberg A; Sundström E; Wahlund LO; Wall A; Wiberg M; Winblad B; Seiger A; Almqvist P; Wahlberg L
    Dement Geriatr Cogn Disord; 2012; 33(1):18-28. PubMed ID: 22377499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.
    Tuszynski MH; Yang JH; Barba D; U HS; Bakay RA; Pay MM; Masliah E; Conner JM; Kobalka P; Roy S; Nagahara AH
    JAMA Neurol; 2015 Oct; 72(10):1139-47. PubMed ID: 26302439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
    Marks WJ; Ostrem JL; Verhagen L; Starr PA; Larson PS; Bakay RA; Taylor R; Cahn-Weiner DA; Stoessl AJ; Olanow CW; Bartus RT
    Lancet Neurol; 2008 May; 7(5):400-8. PubMed ID: 18387850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of rAAV2-mediated NGF gene delivery in adult and aged rats.
    Wu K; Meyers CA; Guerra NK; King MA; Meyer EM
    Mol Ther; 2004 Feb; 9(2):262-9. PubMed ID: 14759810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.
    Eyjolfsdottir H; Eriksdotter M; Linderoth B; Lind G; Juliusson B; Kusk P; Almkvist O; Andreasen N; Blennow K; Ferreira D; Westman E; Nennesmo I; Karami A; Darreh-Shori T; Kadir A; Nordberg A; Sundström E; Wahlund LO; Wall A; Wiberg M; Winblad B; Seiger Å; Wahlberg L; Almqvist P
    Alzheimers Res Ther; 2016 Jul; 8(1):30. PubMed ID: 27389402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AAV2/5-mediated NGF gene delivery protects septal cholinergic neurons following axotomy.
    Wu K; Meyer EM; Bennett JA; Meyers CA; Hughes JA; King MA
    Brain Res; 2005 Nov; 1061(2):107-13. PubMed ID: 16226726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-132 and early growth response-1 in nucleus basalis of Meynert during the course of Alzheimer's disease.
    Zhu QB; Unmehopa U; Bossers K; Hu YT; Verwer R; Balesar R; Zhao J; Bao AM; Swaab D
    Brain; 2016 Mar; 139(Pt 3):908-21. PubMed ID: 26792551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients.
    Bartus RT; Baumann TL; Siffert J; Herzog CD; Alterman R; Boulis N; Turner DA; Stacy M; Lang AE; Lozano AM; Olanow CW
    Neurology; 2013 Apr; 80(18):1698-701. PubMed ID: 23576625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.
    Tuszynski MH; Thal L; Pay M; Salmon DP; U HS; Bakay R; Patel P; Blesch A; Vahlsing HL; Ho G; Tong G; Potkin SG; Fallon J; Hansen L; Mufson EJ; Kordower JH; Gall C; Conner J
    Nat Med; 2005 May; 11(5):551-5. PubMed ID: 15852017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer's dementia.
    Kuhn J; Hardenacke K; Lenartz D; Gruendler T; Ullsperger M; Bartsch C; Mai JK; Zilles K; Bauer A; Matusch A; Schulz RJ; Noreik M; Bührle CP; Maintz D; Woopen C; Häussermann P; Hellmich M; Klosterkötter J; Wiltfang J; Maarouf M; Freund HJ; Sturm V
    Mol Psychiatry; 2015 Mar; 20(3):353-60. PubMed ID: 24798585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice.
    Meloni M; Descamps B; Caporali A; Zentilin L; Floris I; Giacca M; Emanueli C
    Diabetes; 2012 Jan; 61(1):229-40. PubMed ID: 22187379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
    Herzog CD; Brown L; Gammon D; Kruegel B; Lin R; Wilson A; Bolton A; Printz M; Gasmi M; Bishop KM; Kordower JH; Bartus RT
    Neurosurgery; 2009 Apr; 64(4):602-12; discussion 612-3. PubMed ID: 19349823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.